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OncogenomeAbstract Malignant transformation of normal cells to cancer cells represents an enigmatic phe-
nomenon because of the many ambiguous controversies embodied within most of its aspects.
Within a clinical context, cancer, with very few exceptions, is a dreadful disease that ends lethally.
Within a biological context, however, cancer is a peculiar biosystem that has its own rules that reg-
ulate the actions/interactions/structure and behavior of its components. Unfortunately, the major-
ity of these rules are, still, unknown.
The current disappointing situation as regards research trials aiming at constructing effective
treatments for cancer might be attributed, in part, to incomplete recognition of the signiﬁcant dif-
ferences between these two contexts of malignant transformation. Although the peculiar character-
istics of cancer as a self-dependent biosystem are well studied and well deﬁned, the basic dilemma of
malignant transformation continues to exist: we know, largely, how things happen but we do not
know, to any extent, why they happen.
Though the logic that motivates researches aiming at formulating genetic therapies for cancer is
quite reasonable, as cancer is primarily a genetic alteration, lack of essential basic knowledge
regarding the different aspects of this alteration adjourn successful radical cure of cancer. Till com-
prehensive disclosure of the underlying mechanisms regulating growth/progression/metastasis and
survival of malignant cells is attained, treatments of cancer based on different strategic concepts,
viz. proteomic therapies rather than genetic therapies, might, hopefully, be the best approaches
available in the ﬁght against cancer in the current as well as in the coming era.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.Contents
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Malignant transformation of normal cells to cancer cells repre-
sents a radical change in the predeﬁned default programing of
the genome. The fate of normal cells is precisely deﬁned
according to a dogma that speciﬁes the course of life at the
molecular level. The genome of the cell dictates the basic char-
acteristics of the cell within the context of the cell population,
tissue or organ as regards essential aspects including growth
and differentiation, timing of cell division, synthesis of prod-
ucts needed for mediating physiological functions, interactions
with adjacent cells, responses to extracellular stimuli and regu-
latory mechanisms, and, most important, cell death when the
mutation load of the cell causes considerable deterioration of
cellular functions and imposes on the cell overburden pressure
that drives it into apoptosis.
Transformation of normal cells to malignant cells implies
numerous changes involving two main aspects of the cell: cell
functions and cell architecture. Functional changes imposed
by malignant transformation present as loss of functions,
acquisition of new functions and quantitative/qualitative
changes of preserved functions. Changes of cell architecture
induced by malignant transformation impart to the cell new
morphological characteristics that differ greatly from the
structural properties of normal cells, and play a detrimental
role in deﬁning the natural history of tumor progression and
metastasis. The marked deviation of the newly acquired struc-
tural and functional characteristics of cancer cells from normal
cells constitutes the framework of the malignant phenotype
which characterizes each type of malignant tumors.
The marked similarity of the phenotype of malignant cells to
that of early embryonic and fetal cells represents an essential
clue to understand and interpret the nature of the genetic alter-
ations involved in the process ofmalignant transformation. This
similarity comprises the general cardinal properties of tumor
cells including enhanced rate of cell division, mass expression/
suppression of large number of genes, resilience and plasticity
of the cell cytoskeleton allowing for cell dissemination/migra-
tion andmetastasis, augmented potential of differentiation/spe-
cialization/growth and, most importantly, altered pathways of
apoptosis which allow for longer survival of cancer cells with
consequent potentiation of the functional proﬁle of the malig-
nant phenotype. This hazardous result of halted or reduced
apoptosis in malignant cells plays a critical role in conferring
the aggressive behavior upon the cells and in maintaining tumor
growth/progression and metastasis, which is the main culprit
responsible for the dreadful end of cancer patients.
2. Genomic reprograming of cancer cell
The nature of the malignant transformation of normal to can-
cer cells is still very far from being completely revealed orproperly understood. Many perplexing phenomena of this
transformation have no interpretation largely because of lack
of sufﬁcient information regarding the underlying mechanisms
involved in this mysterious biological behavior of cells. For
instance, though some aspects of the malignant phenotype
impart many selective advantages to the malignant cell, on
the whole cancer represents the most disadvantageous fate of
the genetic material that initiates and maintains this pheno-
type. In direct contradiction to basic concepts of biological
evolution, the selective advantages conferred upon the cell by
the malignant phenotype paradoxically result in self destruc-
tion and ﬁnal extinction, rather than preservation, of the
genome.
Reversion to the early embryonic/fetal state is the most
remarkable genomic alteration that characterizes the malig-
nant phenotype. This radical change is reﬂected, not only
in altered cell functions and cell morphology, but also in
the behavior of many types of tumors that aim at formation
and establishment of a new creature, like malignant terato-
mas. To a lesser degree, the incongruous formation of
incompletely differentiated tissues and incomplete/malformed
parts of organs, and the apparently haphazardous transcrip-
tion and synthesis of products, RNA/proteins/hormones/
enzymes/etc., by metastatic tumors, might be considered
within the same context. These observations might suggest
the preservation of the evolutionary ability of the zygote
to develop into a fully-developed organism, by descendant
cells, particularly malignant cells. This reversion to the initial
original genetic proﬁle suggests the maintenance of the struc-
tural and functional phenotype of differentiated normal cells
by genomic regulatory mechanisms controlled by master
genes, probably through synthesis of mass silencers or sup-
pressor molecules capable of keeping the rest of functionally
unneeded genes in differentiated cells in a suppressed state.
Disruption of these regulatory mechanisms would result in
cessation and removal of mass suppression, with consequent
mass reactivation, of non-functioning genes. It might also
result in suppression of already functioning genes. These
contrasting genetic alterations reﬂect and represent the
actual reprograming, or more accurately deprograming, pro-
cess of the genome of normal cells that, probably, paves
the way toward the transformation to cancer cells and the
establishment/initiation and progression of the malignant
phenotype.
3. Genomic involution and hypodiploidy in caner
In view of the complexity of the myriad of interconnected and
interacting regulatory mechanisms that control and determine
all structural and functional aspects of the cell, it is very difﬁ-
cult to accept the monoclonal theory of oncogenesis that attri-
butes tumor development to a triggering mutational event in
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mediated by large numbers of proteins synthesized by large
numbers of genes, and mutations affecting one or even few
genes implicated in carcinogenesis, e.g., tumor suppressor
genes/proto-oncogenes, cannot have such an extensive global
effect on the integrity and stability of the genome unless they
affect critical segments of the genome responsible for global
regulation of the rest of the genome. Unfortunately, no such
critical segments have been deﬁned or, even, delineated. Sec-
ond, most mutations have detrimental effects on one or more
aspects of cellular functions, especially those mutations affect-
ing cancer related genes, most of which are responsible for, and
involved in, regulating the cell cycle. Accordingly, such muta-
tional events leading to unexpected paradoxical effects that
confer selective advantages upon the mutant cancer cell, like
enhanced rate of cell division/prolonged survival and acquisi-
tion of new regenerative abilities, are better considered within
a different context. Third, many types of cancer have astonish-
ing, marked degrees of hypodiploidy, and to a lesser extent,
hyperdiploidy. The ability of some malignant cells with as
few number of chromosomes, as thirty chromosomes only,
to retain their fully developed malignant phenotype and
maintain their aggressive behavior in spite of loss of a consid-
erable part of the genome, with consequent absence of a siz-
able portion of the proteome, raises many queries regarding
the nature of the underlying mechanisms involved in karyotyp-
ic evolution in cancer cells, and the nature of the possible geno-
mic alterations that might compensate for such a conspicuous
diminution of the genome size and the concomitant decrease in
the transcriptome/proteome products.
The sustainment of the malignant phenotype in spite of
marked hypodiploidy might be interpretable by many theoret-
ical hypotheses. For instance, loss, or abandonment, of many
non-vital or crucial functions of the differentiated normal cell
upon undergoing malignant transformation would allow the
cell to survive in absence of genes that regulate these functions.
Over expression of the hypodiploid genome with sufﬁcient
near-threshold transcription/synthesis and/or partial replace-
ment of deﬁcient products might also allow for survival of
malignant cells with marked hypodiploidy. An additional
theoretical hypothesis entails functional complementation
between different clones/strains/progenies of malignant cells
within the tumor that have varying degrees of chromosomal
hypodiploidy, with distinctive functional proﬁle of each.4. Stem cell origin of cancer
Many hypotheses regarding the origin of tumors from adult
stem cells have been postulated based, mainly, on the striking
parallels that can be found between stem cells and cancer cells
as regards self-renewal property [1]. Later identiﬁcation of
cancer stem cells (CSCs); cancer cells found within solid
tumors and hematological malignancies that possess character-
istics associated with normal stem cells speciﬁcally the ability
to give rise to all cell types found in a particular cancer sample,
added support to this hypothesis. Furthermore, cancer stem
cells are considered to be signiﬁcantly responsible for growth,
metastasis, invasion and recurrence of all cancers [2]. These
postulations attributing carcinogenesis to be evoked by trans-
formation changes of stem cells would be more reasonable
than traditional postulations attributing it to mutationalevents of proto-oncogenes or tumor suppressor genes of nor-
mal cells. The reason is obvious as induction of reversion of
stem cells, programed for ready transformation to pluripo-
tent/multipotent cells with phenotypic properties shared by
cancer cells, by few mutational or reprograming processes of
the genome is more rational than attributing this radical and
conspicuous alteration of the genetic constitution of the cell
to one or few carcinogenic mutational events affecting
cancer-related genes.5. Comparative genetics of tumors in humans, animals and plants
Carcinogenesis and tumor formation in animals seem to be ini-
tiated and regulated by the same mechanisms responsible for
tumor development in humans. Shared parallels between
human and animal cancers comprise the main functional
properties and morphological features that constitute the
malignant phenotype and include mutations of speciﬁc
oncogenes and/or tumor suppressor genes, altered pathways
of apoptosis, markedly increased proliferation indices, defec-
tive DNA repair, modiﬁcation of inter cellular connections
and adhesion molecules, induction of angiogenesis, epithe-
lial–mesenchymal transition and metastasis to distant sites.
The great similarity between mechanisms of oncogenesis in
humans and animals is expected in view of the shared genetic
biosystems between both of them.
Contrary to what might be thought of, tumors are among
the most widespread abnormalities of plant morphogenesis.
Plant tumors, seem to be initiated and regulated by mecha-
nisms different from those of human and animal tumors. In
addition, they have unique characteristics. First, they might
be caused by infection with viruses, bacteria, arthropods and
worms, with crown-gall tumors caused by the bacterium
Agrobacterium tumefaciens being the most common. Second,
tumors may be formed in plants with speciﬁc genotypes and
are referred to as genetic tumors. Plant tumors forming upon
infection with A. tumefaciens are caused by conjugative trans-
fer of DNA segment (T-DNA) from the bacterial tumor-induc-
ing (Ti) plasmid, and in most dicotyledonous and some
monocotyledonous plants malignant transformation leading
to abnormal division/defective differentiation results from
alteration in hormonal level or changes in hormone sensitivity
induced by the activity of the plasmid genes integrated with the
infected plant genome [3].
Although pathogenetic mechanisms underlying tumor for-
mation in plants are poorly studied, currently deﬁned func-
tional aspects of plant hormones might have important
implications for cancer therapy in humans. The leading role
played by hormones in tumor development in plants is attrib-
uted to their global regulatory functions that control, nearly,
all aspects of plant life. Plants, unlike animals, lack glands that
produce and secrete hormones, instead, each plant cell is capa-
ble of producing hormones. Unlike speciﬁc physiological func-
tions of hormones in human/animal cells, plant hormones, or
phytohormones, regulate cellular processes in targeted cells
locally and, when moved to other locations, in other locations
of the plant. Plant hormones determine the formation of ﬂow-
ers, stems, leaves, the shedding of leaves, and the development
and ripening of fruit. They also shape the plant, affecting seed
growth, time of ﬂowering, the sex of ﬂowers, senescence of
leaves, and fruits. They affect which tissues grow upward
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fruit development and ripening, plant longevity, and even
plant death. Hormones are vital to plant growth, and, lacking
them, plant cells could neither grow nor differentiate, and
plant hormones play pivotal regulatory roles in activating cel-
lular responses, including cell death, to diverse stress situations
in plants. Five major classes of plant hormones, some of which
are made up of many different chemicals that can vary in struc-
ture from one plant to the next have been deﬁned including
Abscisic acid, Auxins, Cytokinins, Ethylene and Gibberellins.
Other hormones with varying functions, e.g., growth
regulators, signaling molecules, defense mediators etc., include
Salicylic acid, Brassinosteroids, Jasmonates, Nitric oxide,
Karrikins and many others [4].
The importance of plant hormones stemmed from observa-
tions regarding their effects on human cancer. For example,
sodium salicylate has been found to suppress proliferation of
lymphoblastic leukemia, prostate, breast, and melanoma
human cancer cells [5], Jasmonic acid has been found to induce
death in lymphoblastic leukemia cells, and methyl jasmonate
has been found to induce apoptosis and cell death in a number
of cancer cell lines [6]. Many researches have revealed the
anticancer/antiviral/antiproliferative actions of many plant
hormones, e.g., Brassinosteroids [7] and the antitumor and
antiangiogenic effects of gibberellin derivatives [8]. In view of
the marked functional versatility of plant hormones in control-
ling nearly all aspects of plant life particularly growth potential
and proliferative properties, they may potentially constitute a
novel class of effective anti-cancer medications.
6. Metastasis of malignant cells
Metastasis of malignant cells might be regulated by mecha-
nisms similar to those regulating movement and decentraliza-
tion of bacterial masses, e.g., quorum sensing pathways [9].
Furthermore, the positive feedback loop of this pathway
including the coordinated synthesis and secretion of the sig-
naling molecules (inducers) and the synthesis of the receptors
with cumulative increase in size of population of the bacteria
bears many similarities to the behavior of metastatic malig-
nant cells.
The recent discovery of one isoform of the tumor suppres-
sor gene p53 (p53w) that may contribute to, rather than pre-
vent, tumorigenesis proposed that increased levels of p53w
will enhance tumor development and aggression by sustaining
the expansion and survival of putative cancer-initiating cells
[10]. This proposed mechanism of the p53w product permits
speculations as regards a possible role of this gene in synthesis
of inducer molecules that might have functional roles as signal-
ing stimuli in the postulated quorum sensing pathway regulat-
ing some aspects of tumor metastasis.
Further support to this theoretical speculation regarding
presumptive role of quorum sensing pathways in tumor metas-
tasis might be deduced from the observation that synchroniza-
tion of the behavior of hundreds of the bacterium Myxococcus
xanthus cells in a growing swarm is, possibly, mediated by
transmission signals. The way such large numbers of cells
expand, align to each other and expand to form mounds or
heaps under the effect of signaling/transmission molecules
reveals, at least partially, how multicellular structures can be
constructed according to an inherited plan [11].The nature of the pathogenetic mechanisms underlying and
mediating metastasis of malignant cells is poorly understood in
spite of tremendous researches aiming at revealing pivotal
aspects of this enigmatic behavior responsible for the lethality
of the vast majority of cancers. Though many leading observa-
tions regarding this behavior have been considered, a common
basic link between these ﬁndings has not been formulated.
Selective genomic reactivation/suppression of genes responsi-
ble for regulating cell movement, cytoskeleton modiﬁcations
and intercellular adhesions resulting in reversion to the early
embryonic/fetal stage where cell migration to, and localization
in, distant organs plays a crucial role in organogenesis,
undoubtedly, has a central regulatory role in tumor metastasis.
Phenotypic alterations of cancer cells necessary for
regaining this property are reﬂected in their ability to regain
and undergo epithelial–mesenchymal transition (EMT), a
transdifferentiation developmental regulatory process involved
in early embryonic development resulting in disruption of
homeostasis of embryonic/fetal epithelial cell and leading to
acquisition of a migratory mesenchymal phenotype responsi-
ble for conducting critical developmental processes. This pro-
cess is considered a crucial mechanism in tumor metastasis.
The importance of cellular transitions in development is ﬁrst
apparent during gastrulation when the process of epithelial
to mesenchymal transition transforms polarized epithelial cells
into migratory mesenchymal cells that constitute the
embryonic and extraembryonic mesoderm [12].
From the above mentioned observations, it seems plausible
to postulate that metastasis of tumor cells might begin and
progress along a strictly regulated multistage process compris-
ing many genetic alterations of the genome/transcriptome/
proteome compartments of the cell. This multistage process
comprises many steps. First, reversion of cells undergoing
malignant transformation to the embryonic/fetal cell stage
with regaining the ability to undergo epithelial–mesenchymal
transition. Second, synthesis of signaling factors and receptor
molecules that predispose malignant cells destined for metasta-
sis to distant locations, to respond and behave in a way similar
to quorum sensing group behavior of bacteria. Third, estab-
lishment of metastatic niche in distant organs, preceded by,
and/or followed by, widespread genetic alterations necessary
for adaptation of metastatic cells to their new microenviron-
ment. Proper interpretation of the different aspects of
metastasis, however, awaits complete understanding of the
predisposing genetic alterations and the actual pathogenetic
mechanisms responsible for initiating and mediating this
process.
7. Immune responses against cancer
The development of immune responses against tumor cells
represents a perplexing phenomenon in biology of cancer.
Though this process, considerably, occupies the focus of
researches trying to design immunotherapies against cancer,
lack of sufﬁcient information about the actual pathogenetic
mechanisms underlying its development hinders research
approaches to design effective drugs in this respect. Since
immune responses develop against foreign or nonself cells or
molecules, their development against cancer cells in the body
raises many queries regarding the true nature of immune
responses developing against self compartments. Many
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causes of this altered behavior of the immune system, but none
of them is satisfactory. For instance, the malignant phenotype
may cause surface exposure of protein molecules that normally
reside in, or are located inside, different cell compartments,
e.g., cell nucleus/cytoplasm/intracellular organelles/etc., and
that are not exposed to the effector cells/humoral networks
of the immune system in normal conditions. Aberrant expres-
sion of tumor-speciﬁc antigens or of tumor-associated antigens
either on cancer cell surface or in intercellular compartments/
micro-environment of tumors will result in initiation of
immune responses against developing cancer.
Synthesis by tumor cells of novel proteins capable of
inciting immune responses might be possible under certain
conditions. Infection with oncogenic viruses followed by
integration of viral genome with speciﬁc sequences of target
genes will result in synthesis of viral proteins or novel proteins
translated by newly formed combinations of viral and host
genomes. Genomic rearrangements caused by deleterious path-
ogenetic mechanisms, e.g., chromosomal breakage/transloca-
tions, might also result in the formation of new transcribing
sequences within functional regions of genes with consequent
synthesis of new proteins. Point mutations leading to synthesis
of structurally defective proteins, e.g., wrong/truncated/longer
proteins by mis-sense/non-sense/re-sense mutations respec-
tively, and small mutations, deletions/duplications/inversions,
can result in creation of new transcribing sequences leading
to synthesis of new proteins which are defective, in most
instances, due to defective or deﬁcient post-translation struc-
tural modiﬁcation, or more signiﬁcantly, that might be located
at wrong intracellular/intercellular sites or on the cell surface
due to defective post-translation trafﬁcking and localization
of synthesized proteins. A different mechanism for attacking
cancer cells by own body immune system comprises synthesis
by tumor cells of proteins capable of neutralizing the effects
of the humoral immune system and/or attacking or binding
to immune cells responsible for recognition of, and differenti-
ation between, self and nonself, thus nullifying their ability to
recognize cancer cells or oncoproteins as foreign nonself
components.
In spite of the major role of the immune system as the main
defense mechanism against infection by different pathogens,
viruses/bacteria/fungi/worms/etc., it plays a minimal role, if
ever, in defending the body against development of malignant
tumors. The reasons of failure of the immune system in
combating cancer are many, and include ability of tumors to
evade the immune system, reduced synthesis of MHC class I
molecules on tumor cell surface thus avoiding detection by
killer T cells, synthesis by tumor cells of protein products that
inhibit the immune response; for example the cytokine TGF-b
which suppresses the activity of macrophages and lymphocytes
and development of immune tolerance against tumor antigens.
Paradoxically, macrophages can promote tumor growth when
tumor cells secrete cytokines that attract macrophages, which
then generate cytokines and growth factors that enhance
tumor growth and metastasis [13]. These disappointing
ﬁndings indicate that immunotherapeutic approaches, e.g.,
cell-based therapies, antibody therapies and cytokine thera-
pies, for treatment of cancer would have minimal impact in
this regard.
The assumption that chronic non-infective inﬂammation
with concomitant activation of the immune system may leadto development of malignancy has been postulated in view of
a number of ﬁndings. First, the inﬂammatory process itself
provides the prerequisite environment for the development of
malignancy as it includes upregulation of mediators of the
inﬂammatory response such as cyclo-oxygenase (COX)-2 lead-
ing to the production of inﬂammatory cytokines and prosta-
glandins which themselves may suppress cell mediated
immune responses and promote angiogenesis. These factors
may also impact on cell growth and survival signaling path-
ways resulting in induction of cell proliferation and inhibition
of apoptosis. Furthermore, chronic inﬂammation may lead to
the production of reactive oxygen species and metabolites such
as malon-di-aldehyde within the affected cells that may in turn
induce DNA damage and mutations and, as a result, be carcin-
ogenic. This assumption proposes that the conditions provided
by a chronic inﬂammatory environment are so essential for the
progression of the neoplastic process that therapeutic interven-
tion aimed at inhibiting inﬂammation, reducing angiogenesis
and stimulating cell mediated immune responses may have a
major role in reducing the incidence of common cancers [14].
Criticism of this assumption rests on many opposing ﬁndings
headed by the fact that the vast majority of tumors develop
without a preceding inﬂammatory condition. Additionally,
the chronic inﬂammation might itself represent immune
responses to early cellular alterations reﬂecting ongoing malig-
nant transformation, rather than a causative factor responsible
for tumor development and progression.8. Genetic imprinting defects in malignant transformation
Following completion of embryogenesis/differentiation/spe-
cialization/development/growth and formation of a fully orga-
nized fetus, the vast majority of genes in somatic cells get
functionally imprinted as inactivated genes, only genes needed
for mediating cellular functions of the cell are kept active.
Large numbers of genes are known to control and regulate dif-
ferent aspects of post-fertilization processes and promote the
exceedingly accelerated rate of growth and proliferation of
embryonic and fetal cells. As the need for the functions of
these genes diminishes markedly after that, these genes get sup-
pressed. This type of time-deﬁned imprinting, or temporal
imprinting, is different from location-deﬁned, or spatial
imprinting, where genes become suppressed or activated by
effects exerted by adjacent chromatin networks, and also from
parent of origin effect, or parental imprinting, where genes
remain active or get silenced according to the male or female
parent they came from. The traditionally held view that some
genes are imprinted applies only to genes affected by parental
imprinting, whereas the majority of genes in somatic cells are
temporally imprinted.
Though identical single or multiple mutational events
affecting the same proto-oncogenes/tumor suppressor genes
in a group of cells can theoretically predispose to malignant
transformation of large number of cells at the same time, syn-
thesis of one or few oncoproteins leading to disturbance of one
or few metabolic networks seems quite insufﬁcient to drive the
cell environment, comprising thousands of networks and much
larger numbers of proteins, to a malignant phenotype. Defects
in maintaining temporal imprinting status of genes, which have
key roles in early development and that become functionally
silenced or suppressed after differentiation and development
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explain some aspects of initiation of malignant transformation.
For example, it can offer a reasonable interpretation to the
postulated reprograming/deprograming processes of critical
centers/regions of the genome that probably initiate the early
alterations/transformations in malignant cells. Additionally,
it might also offer a conceivable interpretation to the possible
pathogenetic mechanisms underlying the development/mainte-
nance and progression of the malignant phenotype as well as
the mechanisms of loss and/or acquisition of many structural
features and functional properties of malignant cells based
on the genomic reversion assumption.9. The evolutionary paradox of cancer
Revealing the nature and the signiﬁcance of the pathogenetic
mechanisms underlying the acquisition of the different mor-
phological features and functional properties of the malignant
phenotype is necessary for proper understanding of the key
steps in carcinogenesis in their temporal order. Still unex-
plained radical widespread reprograming/deprograming of
the genome heralds the ﬁrst step toward establishment of a
new/different functional framework of the basic life constitu-
ents of the cell, the genome/the transcriptome/the proteome.
Concomitant crucial changes of the transcriptome proﬁle fol-
low and result in extensive reframing and delineation of most
functional/structural networks of the cell, metabolic networks/
signaling networks/growth-proliferation networks/cell migra-
tion networks/etc., mediated by the new/altered proteome pro-
ﬁle of the cell. Each newly constructed/different network
comprising the newly synthesized proteins, in addition to ori-
ginal proteins as well, begins to confer its novel regulatory
functions upon cell constituents involved in performing these
functions. This sequence of events results in establishment of
a new phenotype at the molecular level as well as on the cellu-
lar level. However, although revealing the nature, the causes
and the spectrum of genomic alterations in malignant cells
are fundamental for understanding the transformation/transi-
tion states of the cells leading to acquisition of the malignant
phenotype, ﬁnal elucidation of the actual pathogenetic mecha-
nisms responsible for conferring this characteristic phenotype
upon cancer cells awaits complete delineation of the spectrum
of proteome alterations and changes in malignant cells since all
aspects of the malignant phenotype are determined and regu-
lated by the proteome proﬁle of the cell. This delineation of
proteome alterations in malignant transformation, apart from
its importance in clarifying many aspects of cancer biology and
cancer genetics, is crucial for designing proper and effective
genetic therapies for cancer based on approaches trying to
manipulate abnormal proteome alterations in cancer cells by
different mechanisms including augmentation of synthesis of
normal instead of oncoproteins, suppression of and blocking
the synthesis of oncoproteins, correction of structurally defec-
tive proteins, correction of trafﬁcking defects of proteins and
delivery of protein molecule capable of inducing selective
inhibition/blockage/disintegration of key networks responsible
for maintaining the malignant phenotype of cancer cells.
Understanding the malignant transformation of cells/devel-
opment and progression of cancer would not be possible
except after revealing the exact genomic components and the
regulatory mechanisms responsible for, and underlying the,growth of a single fertilized cell, the zygote, to a fully devel-
oped organism. Meticulous analysis of currently known
facts/ﬁndings/observations related to the phenomenon of
malignant transformation of normal cells to cancer cells adds
more support to the hypothesis attributing carcinogenesis to
defective temporal imprinting, not only of genes that regulate
cell growth/proliferation and differentiation in early stages of
development, but also of a wide spectrum of genes acting
cooperatively in synchronization within a strictly deﬁned
framework comprising the three main constituents of the
genetic material, viz. the genome/the transcriptome/the prote-
ome, and aiming at preservation of the three main features of
biological life, viz. genetic integrity/genetic stability/genetic
identity. The behavior of malignant tumors is conceivable
and clearly interpretable within the context of biological evolu-
tion as acquisition of a new phenotype with selective advanta-
ges over the current conventional phenotype, proliferation,
spread, suppression of apoptosis, metastasis and formation
of new tumors at multiple sites can be looked at as persistent
trials to expand the size of the genome and to improve its sur-
vival potential, compared to mother cells. Paradoxically, in
contrast to expected evolutionary improvements, the behavior
of malignant cells results in deleterious effects on the organism
leading to loss of integrity of the genome as observed in occur-
rence of marked hypodiploidy/hyperdiploidy of tumor cells,
loss of genomic stability caused by, and observed as, small
and large deletions/enhanced rates of chromosomal rearrange-
ments/breaks and structural aberrations detected in most can-
cer cells during most of their life spans, as well as loss of
genomic identity due to acquisition of new different distinctive
phenotypes that bear little resemblance to those of the parent
phenotypes and that get more divergent along their progressive
course of spread and survival. There is no satisfactory explana-
tion of this paradoxical fate of malignant cells characterized by
ﬁnal extinction in spite of the marked selective advantages they
have over normal cells. Also, there is no indication of possible
formulation of such an interpretation in the near, or even in
the far, future. Malignant transformation, at the end, might
prove to be the biological mechanism responsible for terminat-
ing life at the molecular level.10. Clonal origin of tumors
There are two main concepts regarding the cellular origin of
cancer. The hypothesis of the monoclonal origin of tumors
proposes that most neoplasms arise from a single cell of ori-
gin, and tumor progression results from acquired genetic var-
iability within the original clone allowing sequential selection
of more aggressive sublines of the mother cell [15]. Within
this context, carcinogenesis has long been considered as a
progressive multistage pathophysiological process induced
by pathogenetic mechanisms leading to malignant transfor-
mation of one single cell turning it into cancer cell and
spreading to its daughter progeny resulting in formation of
a tumor.
The opposing hypothesis that postulates the polyclonal ori-
gin of tumors, attributes tumor development to a situation
where two or more cells or clones of cells interact to initiate
a tumor. This postulation rests on a number of ﬁndings includ-
ing numerous examples, encompassing 24 different types, of
tumors with X-linked marker heterotypy, unequivocal demon-
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human tumors, mutational data consistent with polyclonal
tumor origin where initiated cells are much more common in
normal tissues than previously realized, and the observation
that while tumors have higher levels of mutation than normal
tissues, oncogenic mutations frequently are present as subpop-
ulations within tumors, rather than as the pure mutant popu-
lations expected to develop from a single initiated cell [16].
As referred previously, it is hard to accept the postulation
of tumor development from a single normal cell that gets
transformed into a malignant cell by one or few mutations
affecting one or more cancer-related genes of the genome.
The malignant phenotype is not a result of just few mutations,
rather it reﬂects a radical widespread change of the genome.
The classical conventional deﬁnition of mutational events
entails any structural changes of parts of the genome, ranging
from change of a single base up to alteration of the whole gen-
ome, that occur either spontaneously or, more commonly,
induced by exogenous environmental mutagens leading to del-
eterious functional consequences. This deﬁnition does not ﬁt
properly, or even approximately, to the types/nature/effects
of mutations leading to malignant transformation. There are
too many reasons for this conclusion. First, whereas most
mutations result in deleterious functional consequences of
affected cells including loss of cellular function(s), induction
of apoptosis and accelerated degeneration and cell death, none
of these detrimental effects are observed in cells undergoing
malignant transformation. Instead, malignant transformation
of normal cells to cancer cells results in acquisition by cancer
cells of new functional and morphological phenotypes encom-
passing numerous selective advantages over normal cells. Sec-
ond, the large scale extensive structural/functional genomic
alterations of the magnitude seen in normal cells undergoing
malignant transformation cannot be caused by, or solely
attributed to, one or few mutations. Third, the obvious pur-
poseful nature of malignant transformation of normal cells
to cancer cells coincides with the conventional rules of biolog-
ical evolution, taking into consideration the numerous selec-
tive advantages conferred upon malignant cells as regards
metabolic competence, proliferative potential, regenerative
abilities, survival span and many others. Although a paradox-
ical fate of cancer cells ﬁnally ensues leading to extinction
rather than preservation/expansion/evolution of the genome,
this happens because of devastating complications related to
the whole organism, e.g., under nutrition/immunodeﬁciency/
organ failure, and does not change the fact that malignant
transformation represents a positive selective advantageous
evolutionary stage of biological life of normal cells undergoing
evolutionary transitions to cancer cells.11. Genetic therapies of cancer
Malignant tumors have many challenging characteristics that
make their effective treatment by currently available conven-
tional approaches an exceedingly hard task to achieve. The
reasons for this conspicuous failure of treatment ofmost tumors
are many. First, tumors begin as tiny growths undetectable by
current imaging techniques and, in most instances, causing no
pathognomonic signs or symptoms except after attaining rela-
tively sizable masses. Second, early metastasis of cancer cells,
adds a tragic aspect to the story as metastatic tumors, whichconstitute the major and commonest cause of death of patients
with cancer, can migrate to multiple sites, grow in many organs
and remain undetected until their overwhelming complications
begin to cause clinical manifestations that allow for their late
diagnosis. Third, in view of considerable lack of knowledge
regarding the, still unrevealed, structural and functional aspects
of malignant cells, no speciﬁc therapy capable of selectively tar-
geting tumor cells exists. Current treatments aiming at inhibit-
ing tumor growth, e.g., antiproliferative chemotherapeutic
agents, or killing tumor cells by different means, e.g., apoptosis
inducing agents and cytotoxic drugs, are not selective against
cancer cells, they rather act indiscriminately on malignant as
well as on normal cells, thus causing damage to both, sometimes
even causing more damage to normal cells because malignant
cells can construct novel metabolic pathways allowing them to
adapt to the effects of these toxic agents. Fourth, the metabolic
consequences of the malignant phenotype on host cells/tissues/
organs are numerous and diverse making their treatment a real
health burden on patients with cancer in view of the multiple
approaches needed to combat these effects. For instance, a
tumor can cause dysfunction of vital organs leading to many
pathophysiological alterations, bone marrow depression lead-
ing to anemia/leukopenia/thrombocytopenia, immune deﬁ-
ciency resulting in recurrent infections, pressure effects on
vital organs and many other consequences and life threatening
complications that necessitate intolerable therapeutic interven-
tion in most cases.
Current therapies for cancer comprise two main
approaches: conventional therapies and genetic therapies.
Conventional therapies of malignant tumors comprise three
main approaches: surgical intervention aiming at radical exci-
sion/removal of early localized tumors or symptomatic debul-
king of large non-excisable tumors, radiotherapy aiming at
damaging malignant tumors in view of their sensitivity to radi-
ations in addition to the direct cytotoxic effects of radiation on
living cells, physical approaches including cryotherapy or cryo-
surgery where killing of cancer cells is attained by freezing by
liquid nitrogen or argon gas, thermal therapy or hyper-thermia
treatment of cancer where high temperature (45 C or 113 F)
is used to kill malignant cells, and laser therapy where laser
lights of different kinds (carbon dioxide (CO2) lasers, argon
lasers, and neodymium:yttrium–aluminum-garnet (Nd:YAG)
lasers) are used to kill tumor cells. Each of these conventional
approaches for cancer treatment (surgical intervention, radio-
therapy and physical techniques) has its indications and its
contraindications, its advantages and disadvantages and its
varied techniques. In view of the marked advances in trials/
researches/applications aiming at improving the technical
aspects of these conventional approaches, it is hoped that
treatment and/or alleviation of a considerable sizable portion
of many types of cancer would be achievable in the future.
Genetic therapies of cancer refer to treatment modalities
designed for, and directed against, the three main constituents
of the genetic material of the cell: the genome, the transcrip-
tome and the proteome, and include innumerable modalities
each aiming at targeting one or more aspects of the malignant
phenotype. Examples of these treatment approaches include
inhibition of cell growth and arrest of cell proliferation, induc-
tion of apoptosis via enhancement of apoptotic pathways,
inhibition of formation of new vascular networks or angiogen-
esis which has a crucial role in maintaining tumor survival and
metastasis, synthesis of antagonistic or interfering oligonucle-
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scribed by oncogenes leading to cessation of synthesis of onco-
proteins, augmentation of the efﬁciency of the immune system
in attacking and embracing malignant cells, functional nulliﬁ-
cation of harmful functions and lethal effects of oncoproteins
by synthesized antibodies speciﬁc for particular oncoproteins,
selective destruction of cancer cells by oncolytic virotherapy
using genetically engineered viruses designed to infect cancer
cells and induce cell death through the propagation of the virus
and expression of cytotoxic proteins leading to tylosis of can-
cer cells, interference with cell growth and changing the inter-
cellular microenvironment surrounding malignant cells by
direct gene transfer approaches, blockage and inhibition of
expression of cell surface oncoproteins that interfere with
intercellular connections and cell adhesion molecules and pave
the way for disintegration/migration/metastasis of cells, block-
age and interference with signaling oncoproteins that have key
roles in mediating crucial intracellular and intercellular func-
tions responsible for maintaining and promoting the malignant
phenotype, enhancing susceptibility of cancer cells to toxic
effects of cytotoxic drugs and antiproliferative agents used to
combat their growth, invention of large numbers of cancer
vaccines or biological response modiﬁers designed to work
by stimulating/restoring/augmenting the immune system’s
ability to ﬁght cancer cells.
The list of therapeutic approaches to genetic therapies of
cancer is endless in view of the functional versatility of tumor
cells. One new emerging approach in this respect, viz. use of
natural products extracted mostly from plants that have pro-
found inhibitory effects on cancer growth and metastasis, how-
ever, is worthy of more consideration as it, probably,
represents the least damaging and more safe treatment modal-
ity for cancer. Examples of these natural products include the
small biologically active ﬂavonoid genistein found in high
amounts in soya [17], many plant hormones that can induce
apoptosis of malignant cells in addition to other anticancer/
antiviral/antiproliferative/antiangiogenic actions including
sodium salicylate [5], Jasmonic acid and methyl jasmonate
[6], Brassinosteroids [7], gibberellin derivatives [8], in addition
to many natural products of plant origin including Vinca alka-
loids/Taxanes (Paclitaxel and docetaxel)/ﬂavopiridol/homo-
harringtonine/b-lapachone/combretastatin A4, of microbial
origin including rapamycin and geldanamycin which are mac-
rolide compounds obtained from Streptomyces hygroscopicus,
and of marine sources that have varied beneﬁcial effects in
inhibiting growth/proliferation/metastasis of malignant cells
and enhancing their susceptibility to toxic effects of cytotoxic
drugs through different mechanisms targeting oncoproteins/
enzymes/signaling pathways/cytoskeleton alterations/etc., [18].
Effective genetic therapies of cancer have to fulﬁll particular
requirements in view of the nature of the disease because of the
numerous pathogenetic mechanisms underlying its initiation/
persistence/progression and the widespread pathophysiological
complications caused by the original tumor as well as by tumor
metastases. In order to be approved for cancer therapy, the
medications used must be selective in action targeting only, if
possible, tumor cells and avoiding as much as possible normal
cells. Complications caused by side effects of cancer medica-
tions must be tolerable and amenable to alleviation by other
therapeutic approaches. Selective targeting of the crucial key
features responsible for mediating the lethal effects of the
malignant phenotype, particularly enhanced proliferation andunopposed apoptosis, angiogenesis and metastasis to distant
organs represents a pivotal goal of research work in this regard.
Unfortunately, current available knowledge about the dif-
ferent functional aspects of the malignant phenotype does
not sufﬁciently allow for designing or synthesis of safe, selec-
tive and effective medications of cancer. However, there are
few guidelines for research efforts in this respect that might
be worthy of consideration.
First, exclusive gene therapy trials aiming at direct targeting
of speciﬁc genes of the cancer cell genome are not expected to
achieve any success, on the contrary, they represent the worst
approaches because of the equal or more damage they cause to
normal cells as well, because of their haphazardous uncontrol-
lable non-selective action(s). Currently deﬁned framework of
cancer biology and the nature of malignant transformation
exclude direct targeting of cancer-related genes from being
an effective treatment approach to cancer.
Second, the theoretical impetus of most immunotherapeu-
tic approaches of cancer treatment is based on the postulation
that tumors develop as a result of defective/deﬁcient function-
ing of the immune system. Though this assumption is partially
correct, it cannot be relied upon for designing or formulating
efﬁcient cancer immunotherapies. Currently available immu-
notherapies for cancer comprise different modalities of cell-
based therapies/antibody therapies/cytokine therapies and
other less common approaches. Most of these modalities
depend on speciﬁc targeting of particular oncoproteins
involved in initiation/progression of tumors. In spite of the
crucial role played by the immune system in defense processes
and preservation of many aspects of biological homeostasis,
its presumed goals in efﬁcient treatment of cancer seem hard
to accomplish. Successful treatment of cancer by immunother-
apeutic agents is limited, practically, to hematological malig-
nancies where separate cells can be targeted individually.
Though targeting of outer border cells of solid tumors can
be achieved by monoclonal antibodies directed selectively
against surface oncoproteins, they have limited, or no, effec-
tiveness beyond this stage when tumors attain sizes and form
growths that can neither be embraced nor penetrated by
immunotherapeutic agents. The efﬁcient capabilities of malig-
nant cells to adapt to counteracting immune factors by differ-
ent means, e.g., synthesis of oncoproteins that kill immune
cells or nullify their detective abilities to detect self from non-
self components, constitute an additional hindrance to devel-
opment of reliable and/or effective immunotherapies of
cancer.
Third, the use of naturally occurring products extracted
from plant/microbial/marine sources in treatment of malig-
nant tumors seems quite promising in view of its apparent
safety and effectiveness, with least harm being induced to nor-
mal cells or to managed patients. However, the need for higher
pharmacological doses of these agents to work efﬁciently and
the possibility of causing side effects due to mixing with other
extracts of the same source necessitates more innovative tech-
niques for puriﬁcation to attain maximal anticancer effects and
maximal clinical safety for managed patients.
Fourth, irrespective of theoretical postulations upon which
different genetic therapeutic approaches to cancer are formu-
lated and designed, ﬁnal success in achieving efﬁcient treat-
ment of cancer depends wholly on accurate comprehensive
delineation of the oncoprotein proﬁle of malignant cells and
on proper understanding and interpretation of the mechanisms
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morphological features of the malignant phenotype. As in nor-
mal cells, where the normal proteome of the cell is responsible
for conducting all cellular functions, the proteome of malig-
nant cells, or the oncoproteome, mediates all life activities of
cancer cells including basic essential features like growth/pro-
liferation/metastasis as well as all subsidiary activities needed
to maintain the malignant phenotype, to consolidate its persis-
tence as well as to augment tumor spread and metastasis.
Fifth, genetic therapeutic approaches to combat cancer
could involve varying treatment modalities targeting any or
all of the genetic constituents of the cancer cell, viz. the gen-
ome, the transcriptome and the proteome. Therapies targeting
the genome are meaningless waste of resources/efforts/time in
view of lack of sufﬁcient knowledge of different aspects of
genomic alterations of malignant cells. Targeting the transcrip-
tome and the intimately related microRNA components, that
have conspicuous pivotal regulatory roles exerted over most
functional genomic regions, is a reasonable approach being
more safer than non-selective random targeting of nuclear
genes. The relative accessibility of the transcriptome, mRNAs,
in the cytoplasm by oligonucleotides is a favorable advantage
for this treatment approach. However, selective targeting of
speciﬁc strand segments is a prerequisite for successful effects,
otherwise, complementation with other transcribing segments
leading to inhibition of translation and synthesis of other use-
ful proteins might result. Similarly, interference with regula-
tory microRNA components needed to maintain the
expression of genes that hinder the progression of malignant
transformation, e.g., through suppression of overexpression
of oncogenes, would result in dreadful consequences leading
to paradoxical enhancement of tumor progression and spread.
Sixth, therapeutic approaches aiming at corrective manipu-
lation of the oncoproteome rather than the genome, the tran-
scriptome or the regulatory microRNA system, represent the
most logical and feasible approaches toward designing radical
effective genetic therapies of cancer as they comprise direct tar-
geting of factors that determine the functional and structural
aspects of the malignant phenotype. Focusing ongoing
researches in this direction would, probably, result in formu-
lating more fruitful treatment modalities for cancer.12. Conclusions
Malignant transformation of normal cells to cancer cells
represents an enigmatic phenomenon because of the many
ambiguous controversies embodied within most of its aspects.
Cancer is a peculiar biosystem that has its own rules that
dictate and regulate all the structural features/functional
properties/interactive potentials of its components. Unfortu-
nately, the majority of these rules are, still, unknown. More
importantly, in view of acquisition of numerous selective
advantages due to the wide spectrum of variations/capabili-
ties/resilience of the proteome of malignant cells, or the
oncoproteome, these rules deﬁned by the malignant phenotype
dominate over conventional biological rules regulating life
aspects of normal cells. Though understanding the genetic
implications of this dominance, including the evolutionary
expansion and progression followed by extinction of the gen-
ome of the malignant cell, or the oncogenome, and the
impaired decay or apoptosis of transformed cells, is criticalfor interpreting the developmental origin and behavior of
tumors, it also comprises an appreciable achievement in reveal-
ing the dynamics of cancer cells which is pivotal in designing
and formulating effective treatment modalities against devel-
opment/progression/metastasis of cancer.
Although the exact nature of the basic cause of develop-
ment of cancer is quite vague, current hypotheses regarding
the pathogenetic mechanisms that possibly underlie develop-
ment of malignant tumors comprise lots of speculations
including defective temporal imprinting of the vast majority
of developmental genes leading to mass reactivation/suppres-
sion of the genome with regaining the characteristic genetic
proﬁles of early embryogenesis and development and sponta-
neous or mutation-induced functional imbalances between
proto-oncogenes/oncogenes/tumor suppressor genes leading
to abnormal/defective/altered regulation of cell division and
growth. Defective parental imprinting might also be implicated
in pathogenesis and development of hereditary tumors.
Irrespective of all suggestions, the development of the
malignant phenotype of cancer cell reﬂects a radical change
of the cell genome. This alteration involves extensive repro-
graming/deprograming of sizable portions of the genome
with consequent reforming of the regions of active/silenced
genes, quantitative transcriptome and micro RNAs compo-
nents and proteome proﬁles. The newly reformed/regained
oncoproteome reforms the cell architecture involving new fea-
tures, some of which are identical to those of embryonic and
fetal cells, and mediates all the functional capabilities of the
malignant cell, thus conferring upon the cell the structural
features and the functional properties of the malignant
phenotype.
Metastasis represents the major cause of lethality of cancer
in view of the progressive and relentless detrimental wide-
spread changes of the structural components and the func-
tional capabilities of tissues and organs affected by
metastases. Though the exact nature of the cause of this mys-
terious behavior of malignant tumors is still obscure, many
mechanisms responsible for mediating and regulating the
dynamics of this process have been revealed including changes
of cell cytoskeleton and cell movement/cell interactions/new
angiogenesis and modulation of the extra cellular microenvi-
ronment. The hypothesis referred to in this article speculating
a similarity of mechanisms regulating tumor cell metastasis
and quorum sensing pathways of bacteria might be worthy
of consideration since detection of postulated regulatory sig-
naling pathways that have a role in tumor metastasis might
pave the way toward designing and formulating effective treat-
ment for this drastic process responsible for lethality of malig-
nant tumors.
Within a clinical context, cancer, with very few exceptions,
is a dreadful disease that ends lethally, whereas within a bio-
logical context cancer is a peculiar biosystem with its own
rules that are largely unknown. The current disappointing sit-
uation as regards research trials aiming at constructing effec-
tive treatments for cancer might be attributed, in part, to
incomplete recognition of the signiﬁcant differences between
these two contexts of malignant transformation. Although
the peculiar characteristics of cancer as a self-dependent bio-
system are well studied and well deﬁned, the basic dilemma
of malignant transformation continues to exist: we know, lar-
gely, how things happen but we do not know, to any extent,
why they happen.
10 M.S.Z. SalemIn spite of the innumerable treatment modalities designed/
constructed/formulated and tried for treatment of most types
of malignant tumors, effective cure of cancer is still very far
from being achieved, desperately even a practical impossibil-
ity. Successful therapy of cancer is dependent on comprehen-
sive understanding of the true nature of the genetic
alterations causing malignant transformation of a normal cell
to cancer cell and disclosure of the underlying mechanisms
regulating growth/progression/metastasis and survival of
malignant cells.
Away from palliative surgical excision/removal/debulking
of tumors, current treatment approaches target one of the
three components of the genetic system of the cell: the genome,
the transcriptome and the proteome. Though the logic that
motivates researches aiming at formulating genome-targeting
therapies for cancer is quite reasonable, as cancer is primarily
a genetic alteration, lack of essential basic knowledge regard-
ing the different aspects of this alteration, in addition to lack
of exclusive selective targeting of genes/segments/regions
responsible for malignant transformation adjourn successful
formulation of such effective genome-targeting therapies.
Transcriptome-targeting therapies and regulatory small/
microRNAs-targeting therapies of cancer are promising
approaches in this respect, however, they are hampered by sim-
ilar lack of sufﬁcient basic knowledge regarding the extremely
wide functional spectrum of their different components and
lack of exclusive selective targeting of these components. Till
comprehensive disclosure of the causes of carcinogenesis is
attained, treatments of cancer based on different strategic con-
cepts, viz. proteomic therapies rather than genomic therapies,
might, hopefully, be the best approaches available in the ﬁght
against cancer in the current as well as in the coming era.
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